Carebook Technologies Past Earnings Performance
Past criteria checks 0/6
Carebook Technologies's earnings have been declining at an average annual rate of -5%, while the Healthcare Services industry saw earnings growing at 15.5% annually. Revenues have been growing at an average rate of 35.9% per year.
Key information
-5.0%
Earnings growth rate
18.6%
EPS growth rate
Healthcare Services Industry Growth | -3.9% |
Revenue growth rate | 35.9% |
Return on equity | n/a |
Net Margin | -22.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Carebook Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 14 | -3 | 6 | 8 |
31 Mar 24 | 13 | -3 | 6 | 7 |
31 Dec 23 | 12 | -3 | 6 | 7 |
30 Sep 23 | 11 | -13 | 4 | 7 |
30 Jun 23 | 10 | -15 | 4 | 7 |
31 Mar 23 | 9 | -16 | 5 | 8 |
31 Dec 22 | 9 | -18 | 6 | 8 |
30 Sep 22 | 9 | -17 | 8 | 9 |
30 Jun 22 | 8 | -18 | 9 | 9 |
31 Mar 22 | 7 | -19 | 9 | 8 |
31 Dec 21 | 6 | -19 | 8 | 8 |
30 Sep 21 | 5 | -14 | 7 | 6 |
30 Jun 21 | 4 | -12 | 6 | 6 |
31 Mar 21 | 3 | -12 | 7 | 5 |
31 Dec 20 | 4 | -11 | 6 | 5 |
30 Sep 20 | 4 | -6 | 5 | 7 |
30 Jun 20 | 4 | -6 | 5 | 6 |
31 Mar 20 | 4 | -3 | 2 | 5 |
31 Dec 19 | 4 | -3 | 2 | 4 |
31 Dec 18 | 3 | -3 | 1 | 0 |
Quality Earnings: CRBK is currently unprofitable.
Growing Profit Margin: CRBK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRBK is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.
Accelerating Growth: Unable to compare CRBK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (24.5%).
Return on Equity
High ROE: CRBK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.